The nephrologist and researcher says the field must move beyond discovery to ensure established therapies reach more patients, while developing more personalised approaches to kidney care.
Katherine R. Tuttle says her career in nephrology began with a clinical realisation: patients with diabetes were living long enough to develop kidney disease, yet the problem was still being missed until it became advanced. In an interview with Healio, the Washington-based physician-researcher said that experience in the mid-1980s pushed her away from physiology alone and towards work aimed at preventing kidney failure, a shift that would later place her among the investigators helping to define a new era in diabetic kidney disease.
That early pivot helped shape a body of research that, as Tuttle has written in the medical literature, contributed to the rise of treatments that now slow kidney decline and protect the heart as well. In a 2019 review in Nature Reviews Nephrology, she highlighted sodium-glucose cotransporter 2 inhibitors, including canagliflozin, as a turning point for diabetic kidney disease, while also noting that many patients still face substantial residual risk. More recent papers by Tuttle and colleagues have argued that the field’s challenge is no longer only scientific discovery, but also ensuring that proven therapies actually reach patients in routine care.
That theme runs through her latest comments to Healio and through related work she has published on implementation science and precision medicine. In a 2022 paper indexed by PubMed, Tuttle and co-authors said the transition from trial evidence to everyday practice must be accelerated so breakthrough treatments are not left underused. In another line of research, she has also stressed the importance of involving patients in the Kidney Precision Medicine Project, saying community engagement is essential if researchers want to design studies that reflect real-world needs rather than abstract scientific priorities.
Tuttle told Healio that the next phase of nephrology should move in two directions at once: broader use of existing therapies and more individualised care based on who responds, who does not, and why. She said the field has made major progress over the past decade, but warned that uptake of established treatment remains far too low. Her argument is that nephrology now has both the tools and the responsibility to act, especially given the scale of chronic kidney disease, which affects roughly one in seven people in the US and remains undiagnosed in most of them.
Beyond the clinic, Tuttle described a life shaped by art, running, skiing and time spent at home in north-eastern Washington, where she lives on 35 acres of forestland with her husband, dogs and grown child. She also pointed to Jonas Salk as a professional hero, praising the polio vaccine pioneer’s focus on public good over personal profit. That instinct, she said, is the standard she hopes the next generation of clinicians and scientists will follow: work on problems that matter, keep going when setbacks come, and let the value of the work speak for itself.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
